natgillin/translations-raw huggingface dataset:
Samtidig administration af axitinib og potente CYP3A4/5-induktorer (f.eks. rifampicin, dexamethason, phenytoin, carbamazepin, rifabutin, rifapentin, phenobarbital og perikon) kan nedsætte plasmakoncentrationen af axitinib.
Co-administration of axitinib with strong CYP3A4/5 inducers (e.g. rifampicin, dexamethasone, phenytoin, carbamazepine, rifabutin, rifapentin, phenobarbital, and Hypericum perforatum [St. John’s wort]) may decrease axitinib plasma concentrations.
Samtidig administration af bedaquilin med lopinavir/ritonavir kan dog foretages med forsigtighed, hvis fordelen opvejer risikoen.
However, if the benefit outweighs the risk, co-administration of bedaquiline with lopinavir/ritonavir must be done with caution.
Samtidig administration af bedaquilin med ritonavir kan dog foretages med forsigtighed, hvis fordelen opvejer risikoen.
However, if the benefit outweighs the risk, co- administration of bedaquiline with ritonavir must be done with caution.
Samtidig administration af boceprevir eller telaprevir har potentialet til at påvirke den intracellulære aktivering og den kliniske antivirale virkning af tenofoviralafenamid negativt, og derfor anbefales samtidig administration af Descovy og boceprevir eller telaprevir ikke.
Co-administration with boceprevir or telaprevir has the potential to adversely affect the intracellular activation and clinical antiviral efficacy of tenofovir alafenamide, therefore co-administration of Descovy and boceprevir or telaprevir is not recommended.
Samtidig administration af boceprevir og Aptivus/ritonavir anbefales ikke.
Co-administration of boceprevir with Aptivus/ritonavir is not recommended.
Samtidig administration af boceprevir og medicin, der inducerer eller hæmmer CYP3A4/5, kan reducere eller øge eksponeringen.
Co-administration of boceprevir with medicines that induce or inhibit CYP3A4/5 could
Samtidig administration af boostet
Concominant administration of
Samtidig administration af boostet PREZISTA og disse glukokortikoider anbefales ikke, medmindre den mulige fordel ved behandlingen opvejer risikoen ved systemiske kortikosteroideffekter.
Concomitant administration of boosted PREZISTA and these glucocorticoids is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects.
Samtidig administration af boostet PREZISTA og quetiapin er kontraindiceret, da quetiapin- relateret toksicitet derved kan øges.
Concomitant administration of boosted PREZISTA and quetiapine is contraindicated as it may increase quetiapine-related toxicity.
Samtidig administration af boostet PREZISTA og ticagrelor er kontraindiceret.
Concomitant administration of boosted PREZISTA with ticagrelor is contraindicated.
Samtidig administration af bosentan og cobicistat kan medføre nedsat plasmakoncentration.
Co-administration of bosentan with cobicistat may lead to decreased cobicistat plasma concentrations.
Samtidig administration af Brimica Genuair med andre antikolinerge og/eller langtidsvirkende lægemidler, der indeholder β2-adrenerg agonist, er ikke blevet undersøgt og anbefales ikke.
Co-administration of Brimica Genuair with other anticholinergic and/or long-acting β2-adrenergic agonist containing medicinal products has not been studied and is not recommended.
Samtidig administration af bupropion med gentagne doser af ritonavir forventes at formindske bupropion- niveauer.
Concurrent administration of bupropion with repeated doses of ritonavir is expected to decrease bupropion levels.
Samtidig administration af canagliflozin og metformin blev undersøgt hos patienter med type 2- diabetes, der opnåede utilstrækkelig kontrol med metformin enten alene eller i kombination med andre glucosesænkende lægemidler.
The co-administration of canagliflozin and metformin has been studied in patients with type 2 diabetes inadequately controlled on metformin either alone or in combination with other glucose-lowering medicinal products.
Samtidig administration af carbamazepin, en potent CYP3A- inducer, kan reducere plasmakoncentrationerne af cobicistat og elvitegravir signifikant, hvilket kan medføre manglende terapeutisk virkning og resistensudvikling.
Co-administration of carbamazepine, a potent CYP3A inducer, may significantly decrease cobicistat and elvitegravir plasma concentrations, which may result in loss of therapeutic effect and development of resistance.
Samtidig administration af ceritinib og CYP3A-substrater, der vides at have et snævert terapeutisk indeks (fx astemizol, cisaprid, ciclosporin, ergotamin, fentanyl, pimozid, quinidin, tacrolimus, alfentanil og sirolimus) og CYP2C9-substrater, der vides at have et snævert terapeutisk indeks (fx phenytoin og warfarin) skal undgås.
Co-administration of ceritinib with CYP3A substrates known to have narrow therapeutic indices (e.g. astemizole, cisapride, ciclosporin, ergotamine, fentanyl, pimozide, quinidine, tacrolimus, alfentanil and sirolimus) and CYP2C9 substrates known to have narrow therapeutic indices (e.g. phenytoin and warfarin) should be avoided.
Samtidig administration af ceritinib og stærke CYP3A/P-gp-inducere nedsætter plasmakoncentrationen af ceritinib.
Co-administration of ceritinib with strong CYP3A/P-gp inducers decreases ceritinib plasma concentrations.
Samtidig administration af Corbilta og non-selektive monoaminooxidase (MAO-A og MAO-B)- hæmmere (f.eks. phenelzin, tranylcypromin).
Coadministration of Corbilta with non-selective monoamine oxidase (MAO-A and MAO-B) inhibitors (e.g. phenelzine, tranylcypromine).
Samtidig administration af CRESEMBA og efavirenz er kontraindiceret.
The concomitant administration of CRESEMBA and efavirenz is contraindicated. .
Samtidig administration af Daklinza og perikon eller andre potente CYP3A4-induktorer er kontraindiceret (se pkt.4.3).
Coadministration of Daklinza with St. John’s wort or other strong inducers of CYP3A4 is contraindicated (see section 4.3).
Samtidig administration af dapagliflozin og metformin
Coadministration of dapagliflozin and metformin
Samtidig administration af dasabuvir og ombitasvir/paritaprevir/ritonavir kan reducere eksponeringen for lægemidler, der metaboliseres af CYP2C19 (f.eks. lansoprazol, esomeprazol, s-mephenytoin), hvilket kan nødvendiggøre dosisjustering/klinisk monitorering.
Co-administration of dasabuvir with ombitasvir/paritaprevir/ritonavir can decrease exposures of medicinal products that are metabolized by CYP2C19 (e.g. lansoprazole, esomeprazole, s- mephenytoin), which may require dose adjustment/clinical monitoring.
Samtidig administration af de orale antidiabetiske præparater metformin, glimepirid, glibenclamid og acarbose resulterede ikke på nogen måde i klinisk relevante farmakokinetiske interaktioner med rosiglitazon.
Concomitant administration of rosiglitazone with the oral anti-diabetic agents metformin, glimepiride, glibenclamide and acarbose did not result in any clinically relevant pharmacokinetic interactions.
Samtidig administration af delamanid med quinoloner
Co-administration of delamanid with quinolones
Samtidig administration af den kraftige cytokrom-P450 3A4 (CYP3A4) enzyminducer rifampicin førte til en reduktion af den systemiske eksponering over for apremilast, hvilket kan føre til et tab af apremilasts virkning.
Co-administration of strong cytochrome P450 3A4 (CYP3A4) enzyme inducer, rifampicin, resulted in a reduction of systemic exposure of apremilast, which may result in a loss of efficacy of apremilast.
Samtidig administration af den potente CYP1A2-hæmmer fluvoxamin og pomalidomid, når ketoconazol var til stede, øgede den gennemsnitlige eksponering for pomalidomid med 107 % (90 % konfidensinterval 91-124 %) sammenlignet med pomalidomid plus ketoconazol.
Co-administration of the strong CYP1A2 inhibitor fluvoxamine with pomalidomide in the presence of ketoconazole, increased mean exposure to pomalidomide by 107% with a 90% confidence interval [91% to 124%] compared to pomalidomide plus ketoconazole.
Samtidig administration af den potente CYP1A2-hæmmer fluvoxamin og pomalidomid, når ketoconazol var til stede, øgede den gennemsnitlige eksponeringen for pomalidomid med 107 % (90 % konfidensinterval 91-124 %) sammenlignet med pomalidomid plus ketoconazol.
Co-administration of the strong CYP1A2 inhibitor fluvoxamine with pomalidomide in the presence of ketoconazole, increased mean exposure to pomalidomide by 107% with a 90% confidence interval [91% to 124%] compared to pomalidomide plus ketoconazole.
Samtidig administration af Descovy med andre lægemidler, der hæmmer P-gp (f.eks. cobicistat, ritonavir, ciclosporin) forventes at øge absorptionen og plasmakoncentrationen af tenofoviralafenamid.
Co-administration of Descovy with other medicinal products that inhibit P-gp (e.g., cobicistat, ritonavir, ciclosporin) are expected to increase the absorption and plasma concentration of tenofovir alafenamide.
Samtidig administration af Descovy og prikbladet perikum anbefales ikke.
Co-administration of Descovy with St. John’s wort is not recommended.
Samtidig administration af dolutegravir og andre lægemidler, der hæmmer disse enzymer kan øge plasmakoncentrationen af dolutegravir (se tabel 1).
Co-administration of dolutegravir and other medicinal products that inhibit these enzymes may increase dolutegravir plasma concentration (see Table 1).
Samtidig administration af dolutegravir og dofetilid er kontraindiceret på grund af potentiel livstruende toksicitet forårsaget af en høj
Dolutegravir and dofetilide co-administration is contraindicated due to potential life-threatening toxicity caused by high dofetilide concentration (see section 4.3).
Samtidig administration af Duaklir Genuair med andre antikolinerge og/eller langtidsvirkende lægemidler, der indeholder β2-adrenerg agonist, er ikke blevet undersøgt og anbefales ikke.
Co-administration of Duaklir Genuair with other anticholinergic and/or long-acting β2-adrenergic agonist containing medicinal products has not been studied and is not recommended.
Samtidig administration af Edarbi 40 og 80 mg med en kalciumkanalblokker (amlodipin) eller et diuretikum af thiazid-typen (chlortalidon) resulterede i yderligere blodtryksreduktion sammenlignet med de andre antihypertensiva alene.
Coadministration of Edarbi 40 and 80 mg with a calcium channel blocker (amlodipine) or a thiazide- type diuretic (chlortalidone) resulted in additional blood pressure reductions compared with the other antihypertensive alone.
Samtidig administration af efavirenz og cobicistat forventes at reducere plasmakoncentrationerne af cobicistat.
Co-administration of efavirenz and cobicistat is expected to decrease cobicistat plasma concentrations.
Samtidig administration af efavirenz og elvitegravir forventes at reducere plasmakoncentrationen af elvitegravir, hvilket kan forårsage svigtende terapeutisk virkning og mulig udvikling af resistens.
Co-administration of efavirenz and elvitegravir is expected to decrease elvitegravir plasma concentrations which may result in loss of therapeutic effect and possible development of resistance.
Samtidig administration af efavirenz og perikon eller naturlægemidler, der indeholder perikon, er kontraindiceret.
Co-administration of efavirenz and St. John’s wort or herbal preparations containing St. John’s wort is contraindicated.
Samtidig administration af eltrombopag og lopinavir/ritonavir (LPV/RTV) kan medføre et fald i koncentrationen af eltrombopag.
Co-administration of eltrombopag with lopinavir/ritonavir (LPV/RTV) may cause a decrease in the concentration of eltrombopag.
Samtidig administration af eltrombopag og OATP1B1-substrater (f.eks. methotrexat) og BCRP- substrater (f.eks. topotecan og methotrexat) skal foregå med forsigtighed (se pkt.
Concomitant administration of eltrombopag and OATP1B1 (e.g. methotrexate) and BCRP (e.g. topotecan and methotrexate) substrates should be undertaken with caution (see section 5.2).
Samtidig administration af elvitegravir og orale antikonceptiva, der indeholder andre progestagener end norgestimat er ikke undersøgt og bør derfor undgås.
Co-administration of elvitegravir with oral contraceptives containing progestagens other than norgestimate have not been studied and, therefore, should be avoided.
Samtidig administration af en enkelt dosis af 10 mg/kg tocilizumab og 10-25 mg MTX, én gang ugentligt, havde ingen klinisk signifikant effekt på MTX-eksponeringen
Concomitant administration of a single dose of 10 mg/kg tocilizumab with 10-25 mg MTX once weekly had no clinically significant effect on MTX exposure.
Samtidig administration af enkelte eller flere doser dexamethason (40 mg/dag) har ingen klinisk relevant virkning på farmakokinetikken af lenalidomid efter gentagne doser (25 mg/dag).
Co-administration of single or multiple doses of dexamethasone (40 mg/ day) has no clinically relevant effect on the multiple dose pharmacokinetics of lenalidomide (25 mg/ day).
Samtidig administration af enoxaparinnatrium og anlæggelse af spinal-/epiduralanæstesi kan resultere i intramedullært hæmatom.
Simultaneous administration of enoxaparin sodium and performance of spinal/epidural anaesthesia can result in intramedullary haematoma.
Samtidig administration af Enurev Breezhaler og oralt inhaleret indacaterol, som er en adrenerg beta2- agonist, havde ingen indvirkning på farmakokinetikken for de to lægemidler under steady state- forhold for begge aktive stoffer.
Concomitant administration of Enurev Breezhaler and orally inhaled indacaterol, a beta2-adrenergic agonist, under steady-state conditions of both active substances did not affect the pharmacokinetics of either medicinal product.
Samtidig administration af Enviage havde ingen signifikant indvirkning på atorvastatins, valsartans, metformins eller amlodipins farmakokinetik.
Co- administration of Enviage had no significant impact on atorvastatin, valsartan, metformin or amlodipine pharmacokinetics.
Samtidig administration af enzalutamid (160 mg én gang dagligt) og orale enkeltdoser af følsomme CYP-substrater hos prostatacancerpatienter resulterede i en 86 % mindskning af AUC for midazolam (CYP3A4-substrat), en 56 % mindskning af AUC for S-warfarin (CYP2C9- substrat) og en 70 % mindskning af AUC for omeprazol (CYP2C19-substrat).
Co-administration of enzalutamide (160 mg once daily) with single oral doses of sensitive CYP substrates in prostate cancer patients resulted in an 86% decrease in the AUC of midazolam (CYP3A4 substrate), a 56% decrease in the AUC of S-warfarin (CYP2C9 substrate), and a 70% decrease in the AUC of omeprazole (CYP2C19 substrate).
Samtidig administration af erlotinib med omeprazol, som er en syrepumpehæmmer, nedsætter erlotinib- eksponering [AUC] og maksimumkoncentrationen [Cmax] med henholdsvis 46 % og 61 %.
Co-administration of erlotinib with omeprazole, a proton pump inhibitor (PPI), decreased the erlotinib exposure [AUC] and maximum concentration [Cmax] by 46% and 61%, respectively.
Samtidig administration af esomeprazol og en CYP3A4-hæmmer, clarithromycin (500 mg to gange dagligt (b.i.d)), resulterede i en fordobling af eksponeringen for esomeprazol (AUC).
Concomitant administration of esomeprazole and a CYP3A4 inhibitor, clarithromycin (500 mg twice a day (b.i.d.)), resulted in a doubling of the exposure (AUC) to esomeprazole.
Samtidig administration af esomeprazol og en kombineret inhibitor af CYP2C19 og CYP3A4 kan resultere i mere end en fordobling af esomeprazoleksponeringen.
Concomitant administration of esomeprazole and a combined inhibitor of CYP2C19 and CYP 3A4 may result in more than doubling of the esomeprazole exposure.
Samtidig administration af etravirin og EVOTAZ forventes at nedsætte atazanavir- og cobicistat-plasmakoncentrationer.
Co-administration of etravirine and EVOTAZ is expected to decrease atazanavir and cobicistat plasma concentrations.
Samtidig administration af Eviplera og andre NNRTI’er frarådes.
It is not recommended to co-administer Eviplera with other NNRTIs.
Samtidig administration af EVOTAZ har potentiale til at øge plasmakoncentrationen af warfarin.
Co-administration with EVOTAZ has the potential to increase warfarin plasma concentrations.
Samtidig administration af EVOTAZ kan medføre højere koncentration af salmeterol og øget risiko for salmeterol- relaterede bivirkninger.
Co-administration with EVOTAZ may result in increased concentrations of salmeterol and an increase in salmeterol- associated adverse events.
Samtidig administration af EVOTAZ og lægemidler, der hæmmer CYP3A kan resultere i øgede plasmakoncentrationer af atazanavir og/eller cobicistat.
Co-administration of EVOTAZ with medicinal products that inhibit CYP3A may result in increased plasma concentration of atazanavir and/or cobicistat.
Samtidig administration af EVOTAZ og lægemidler, som er moderat til svage CYP3A-induktorer kan resultere i nedsatte plasmakoncentrationer af atazanavir og/eller cobicistat, hvilket medfører tab af terapeutisk effekt og mulig udvikling af resistens over for atazanavir.
Co-administration of EVOTAZ with medicinal products that are moderate to weak inducers of CYP3A may result in decreased plasma concentration of atazanavir and/or cobicistat, leading to loss of therapeutic effect and possible development of resistance to atazanavir.
Samtidig administration af Exviera og lægemidler, der er stærke eller moderate enzym-inducere, forventes at nedbringe plasmakoncentrationen af dasabuvir og nedsætte dasabuvirs terapeutiske virkning (se pkt.
Co-administration of Exviera with medicinal products that are strong or moderate enzyme inducers is expected to decrease dasabuvir plasma concentrations and reduce its therapeutic effect (see section
Samtidig administration af fentanyl og et serotonergt middel, for eksempel en selektiv serotonin- genoptagelseshæmmer (SSRI) eller en serotonin-norepinephrin-genoptagelseshæmmer (SNRI) eller en monoaminoxidasehæmmer (MAO-hæmmer), kan forhøje risikoen for serotoninsyndrom, en potentielt livstruende tilstand.
Co-administration of fentanyl with a serotoninergic agent, such as a Selective Serotonin Re-uptake Inhibitor (SSRI) or a Serotonin Norepinephrine Re-uptake Inhibitor (SNRI) or a Monoamine Oxidase Inhibitor (MAOI), may increase the risk of serotonin syndrome, a potentially life-threatening condition.
Samtidig administration af fibrater, statiner, danazol, ciclosporin eller potent cytokrom P450 (CYP) 3A4-hæmmere (se pkt.
Concomitant administration of fibrates, statins, danazol, ciclosporin or potent cytochrome P450 (CYP) 3A4 inhibitors (see section 4.5)
Samtidig administration af flere doser af den potente P-gp-hæmmer quinidin (600 mg, to gange dagligt) eller den moderate P- gp-hæmmer/substrat temsirolimus (25 mg) har ingen klinisk relevant virkning på lenalidomids farmakokinetik (25 mg).
Co-administration of multiple doses of the strong P-gp inhibitor quinidine (600 mg, twice daily) or the moderate P-gp inhibitor/substrate temsirolimus (25 mg) has no clinically relevant effect on the pharmacokinetics of lenalidomide (25 mg).
Samtidig administration af flere doser på 10 mg lenalidomid havde ingen virkning på R- og S- warfarins enkeltdosisfarmakokinetik.
Co-administration of multiple doses of 10 mg of lenalidomide had no effect on the single dose pharmacokinetics of R- and S- warfarin.
Samtidig administration af fosaprepitant og aktive substanser, som er stærke induktorer af CYP3A4- aktivitet (fx rifampicin, phenytoin, carbamazepin, phenobarbital) bør undgås, da kombinationen medfører reducerede plasmakoncentrationer af aprepitant, hvilket kan resultere i nedsat virkning.
Concomitant administration of fosaprepitant with active substances that strongly induce CYP3A4 activity (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital) should be avoided as the combination could result in reductions of the plasma concentrations of aprepitant that may result in decreased efficacy.
Samtidig administration af fosaprepitant og urtemedicin, der indeholder perikon (Hypericum perforatum), frarådes.
Concomitant administration of fosaprepitant with herbal preparations containing St. John’s Wort (Hypericum perforatum) is not recommended.
Samtidig administration af følgende lægemidler på grund af den potentielle risiko for alvorlige og/eller livstruende bivirkninger (se pkt.
Co-administration with the following medicinal products due to the potential for serious and/or life- threatening adverse reactions (see section 4.5):
Samtidig administration af følgende lægemidler, som er kraftige induktorer af CYP3A4-isoformen af cytochrom-P450 på grund af den potentielle risiko for tab af terapeutisk virkning (se pkt.
Co-administration with the following medicinal products that are strong inducers of the CYP3A4 isoform of cytochrome P450 due to the potential for loss of therapeutic effect (see section 4.5): carbamazepine, phenobarbital, phenytoin (antiepileptics)
Samtidig administration af gentagne doser af 10 mg amlodipin sammen med 80 mg simvastatin resulterede i en 77 % stigning i eksponeringen for simvastatin sammenlignet med simvastatin alene.
Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone.
Samtidig administration af gentagne doser trametinib 2 mg én gang daglig og dabrafenib 150 mg 2 gange dagligt medførte ikke klinisk relevante ændringer i Cmax og AUC for trametinib eller dabrafenib, med stigninger på henholdsvis 16 % og 23 % i dabrafenib-Cmax og -AUC.
Co-administration of repeat dosing of trametinib 2 mg once daily and dabrafenib 150 mg twice daily resulted in no clinically meaningful changes in trametinib or dabrafenib Cmax and AUC with increases of 16 and 23%, respectively, in dabrafenib Cmax and AUC.
Samtidig administration af Genvoya og nogle lægemidler, der primært metaboliseres af CYP3A, kan føre til øgede plasmakoncentrationer af disse præparater, hvilket er forbundet med risikoen for alvorlige eller livstruende bivirkninger, såsom perifer vasospasme eller iskæmi (f.eks. dihydroergotamin, ergotamin, ergometrin) eller myopati, herunder rhabdomyolyse (f.eks. simvastatin, lovastatin) eller langvarig eller øget sedering eller respirationsdepression (f.eks. oralt administreret midazolam eller triazolam).
Co-administration of Genvoya and some medicinal products that are primarily metabolised by CYP3A may result in increased plasma concentrations of these products, which are associated with the potential for serious or life-threatening adverse reactions such as peripheral vasospasm or ischaemia (e.g., dihydroergotamine, ergotamine, ergometrine), or myopathy, including rhabdomyolysis (e.g., simvastatin, lovastatin), or prolonged or increased sedation or respiratory depression (e.g., orally administered midazolam or triazolam).
Samtidig administration af Genvoya og nogle lægemidler, som inducerer CYP3A såsom perikon (Hypericum perforatum), rifampicin, carbamazepin, phenobarbital og phenytoin kan føre til signifikant reducerede plasmakoncentrationer af cobicistat og elvitegravir, hvilket kan forårsage svigtende terapeutisk virkning og udvikling af resistens (se pkt.
Co-administration of Genvoya and some medicinal products that induce CYP3A such as St. John’s wort (Hypericum perforatum), rifampicin, carbamazepine, phenobarbital, and phenytoin may result in significantly decreased cobicistat and elvitegravir plasma concentrations, which may result in loss of therapeutic effect and development of resistance (see section 4.3).
Samtidig administration af hepatotoksiske eller hæmatotoksiske DMARD’er (f.eks. methotrexat) er ikke tilrådelig.
Concomitant administration of hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) is not advisable.
Samtidig administration af hepatotoksiske eller hæmatotoksiske DMARD’s (f.eks. methotrexat) er ikke tilrådelig.
Concomitant administration of hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) is not advisable.
Samtidig administration af hepatotoksiske eller hæmatotoksiske DMARD’s (f.eks. methotrexate) er ikke tilrådelig.
Concomitant administration of hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) is not advisable.
Samtidig administration af hormonale kontraceptiva
Co-administration with hormonal contraceptives
Samtidig administration af hormonel kontraception
Co-administration with hormonal contraceptives